Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles.
Sugo T, Terada M, Oikawa T, Miyata K, Nishimura S, Kenjo E, Ogasawara-Shimizu M, Makita Y, Imaichi S, Murata S, Otake K, Kikuchi K, Teratani M, Masuda Y, Kamei T, Takagahara S, Ikeda S, Ohtaki T, Matsumoto H. Sugo T, et al. Among authors: teratani m. J Control Release. 2016 Sep 10;237:1-13. doi: 10.1016/j.jconrel.2016.06.036. Epub 2016 Jun 29. J Control Release. 2016. PMID: 27369865
In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs).
Ohoka N, Okuhira K, Ito M, Nagai K, Shibata N, Hattori T, Ujikawa O, Shimokawa K, Sano O, Koyama R, Fujita H, Teratani M, Matsumoto H, Imaeda Y, Nara H, Cho N, Naito M. Ohoka N, et al. Among authors: teratani m. J Biol Chem. 2017 Mar 17;292(11):4556-4570. doi: 10.1074/jbc.M116.768853. Epub 2017 Feb 2. J Biol Chem. 2017. PMID: 28154167 Free PMC article.
Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.
Iwai K, Yaguchi M, Nishimura K, Yamamoto Y, Tamura T, Nakata D, Dairiki R, Kawakita Y, Mizojiri R, Ito Y, Asano M, Maezaki H, Nakayama Y, Kaishima M, Hayashi K, Teratani M, Miyakawa S, Iwatani M, Miyamoto M, Klein MG, Lane W, Snell G, Tjhen R, He X, Pulukuri S, Nomura T. Iwai K, et al. Among authors: teratani m. EMBO Mol Med. 2018 Jun;10(6):e8289. doi: 10.15252/emmm.201708289. EMBO Mol Med. 2018. PMID: 29769258 Free PMC article.
Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
Farrell P, Shi L, Matuszkiewicz J, Balakrishna D, Hoshino T, Zhang L, Elliott S, Fabrey R, Lee B, Halkowycz P, Sang B, Ishino S, Nomura T, Teratani M, Ohta Y, Grimshaw C, Paraselli B, Satou T, de Jong R. Farrell P, et al. Among authors: teratani m. Mol Cancer Ther. 2013 Apr;12(4):460-70. doi: 10.1158/1535-7163.MCT-12-0657. Epub 2013 Jan 28. Mol Cancer Ther. 2013. PMID: 23358665
[Analysis of resolution of CNV (author's transl)].
Matsuda T, Teratani M, Kakigi S. Matsuda T, et al. Among authors: teratani m. Shinrigaku Kenkyu. 1980 Oct;51(4):203-6. doi: 10.4992/jjpsy.51.203. Shinrigaku Kenkyu. 1980. PMID: 7230542 Japanese.
14 results